S. Weitman et al., The new dioxolane, (-)-2 '-deoxy-3 '-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts, CLIN CANC R, 6(4), 2000, pp. 1574-1578
There is a great need for new therapeutic agents for patients with advanced
pancreatic cancer. The new dioxolane analogue troxacitabine was evaluated
in two human pancreatic cancer xenograft models. The models used included t
he Panc-01 and MiaPaCa pancreatic cancer cell, lines. Whereas there is cert
ainly no absolute evidence that either of the in vivo models is predictive
for clinical activity, there is at least some evidence that they may be hel
pful in selecting agents for clinical trials in patients with pancreatic ca
ncer. Troxacitabine was administered i.v. to the animals at doses of 10 and
25 mg/kg on a daily x 5 regimen. Gemcitabine was used as a positive contro
l, The end points for the study included tumor growth inhibition (TGI), fin
al weight, and the number of partial and complete tumor responses in the an
imals, Troxacitabine was highly active against the Panc-01 model (n = 8), w
ith TGI levels of 88.5% and 84.3% at the 10 and 25 mg/kg doses, respectivel
y. The mean final tumor weights for animals given troxacitabine were also s
ignificantly smaller (P < 0.001) compared with vehicle controls. At the 10
mg/kg dose, there were three partial tumor shrinkages and one complete tumo
r shrinkage, whereas at the 25 mg/kg dose, there were three partial tumor s
hrinkages. Troxacitabine had less activity against the MiaPaCa model (n = 1
0) and, by traditional response criteria, would be considered inactive, wit
h TGIs of 4% and 22.7% at the 10 and 25 mg/kg dose level, respectively. Of
note is that in comparison with gemcitabine, troxacitabine was more efficac
ious against Panc-01 and was equally active against MiaPaCa. These in vivo
results are encouraging and support the prospect of performing Phase II and
perhaps Phase III trials with troxacitabine in patients with advanced panc
reatic cancer.